HKPD vs HLF
Cellyan Biotechnology Co. Ltd. and Herbalife Ltd., side by side — 3 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | HKPD | HLF |
|---|---|---|
| Revenue | $20.3M | $5.0B |
| Net income | $-27,056 | $228.3M |
| Gross margin | 11.9% | 77.9% |
| Net margin | −0.1% | 4.5% |
| Return on equity | −0.6% | 364.1% |
| Diluted EPS | −$0.00 | $2.20 |
| Dividend / share | — | $0.30 |
| Payout ratio | — | 0.0% |
| Free cash flow | $499,298 | $252.9M |
| Equity | $5.0M | $-515.1M |
| Net debt / equity | 0.23× | 3.01× |
| Current ratio | 2.99× | 1.13× |
| Revenue CAGR 5y | — | −1.9% |
| Profit CAGR 5y | — | −9.3% |
HLF bills 248.0× the revenue of HKPD, and HKPD closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
3 years side by side
| Fiscal year | HKPD | HLF |
|---|---|---|
| FY2024 | $20.3M | $5.0B |
| FY2023 | $16.7M | $5.1B |
| FY2022 | $12.6M | $5.2B |
Net income by year
Bottom line
| Fiscal year | HKPD | HLF |
|---|---|---|
| FY2024 | $-27,056 | $254.3M |
| FY2023 | $1.3M | $142.2M |
| FY2022 | $998,196 | $321.3M |
Advertisement
AdSense · Rectangle 336×280